2023-04-25 11:58:17 ET
- Stoke Therapeutics ( NASDAQ: STOK ) stock rose ~5% on Tuesday after the company said that U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) authorized an application seeking to start a phase 1/2 trial of STK-002 to treat autosomal dominant optic atrophy (ADOA).
- ADOA is an eye disorder in which there is degeneration of the optic nerves causing impaired vision.
- Stoke noted that STK-002 is a proprietary antisense oligonucleotide ( ASO ) being developed as the first potential disease-modifying treatment to address the genetic cause of ADOA.
- The phase 1/2 trial, dubbed OSPREY, will enroll children and adults aged six to 55 years with ADOA and have evidence of a genetic mutation in the OPA1 gene.
- The company expects enrollment and dosing to start in early 2024.
For further details see:
Stoke stock rises after UK regulator nod to start trial of eye disorder drug